CeNeS starts New Year

CeNes Pharmaceuticals firmed 0.37p to 8.25p amid talk that the company could be given the green light by US regulators to start Phase III clinical trials of M6G, its treatment for severe post-operative pain, early in the new year. Last week, the CeNes chairman Alan Goodman declared the purchase of 500,000 shares at 8p and its chief executive Neil Clark picked up 120,000 shares at the same price